Dose reductions are not recommended for Perjeta and Trastuzumab (see Trastuzumab IV prescribing information). For chemotherapy dose
Perjeta (pertuzumab). The purpose of this form is to obtain information Have the prescribing physician complete the Physician Information sections.
PERJETA should be discontinued if trastuzumab or trastuzumab hyaluronidase-oysk treatment is discontinued. Dose reductions are not recommended for PERJETA. For chemotherapy dose modifications, see relevant prescribing information. Left Ventricular Ejection Fraction (LVEF)
access the prescribing information for both Perjeta and Kadcyla so any viewers would be clear as to the licensed indication for these
Please see full Prescribing Information, including Patient Product Information. Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A.
PERJETA and trastuzumab can be given in any order. 1,2 Please see the PERJETA full Prescribing Information for additional dosing information for PERJETA trastuzumab. PHESGO gives you an opportunity to save time for your patients and practice 1,2
dThe infusion time of minutes may be used at the discretion of the prescribing consultant. information/perjeta-epar-product-.
The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) Notably, prescribing information for the combination includes a
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PERJETA safely and effectively. See full prescribing information for PERJETA. PERJETA (pertuzumab) injection, for intravenous use . Initial U.S. Approval: 2024 . WARNING: LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY
Comments